Lodovico Terzi di Bergamo, MD

Institute of Oncology Research, Università della Svizzera Italiana
Bellinzona, Switzerland

NA

Presentation(s):

• (1498877) XPO1 mutations identify early stage CLL characterized by shorter time to first treatment and enhanced BCR signaling

  Friday, October 6, 2023
  11:35 AM – 11:40 AM EDT